Juulia Jarvinen
Overview
Explore the profile of Juulia Jarvinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Retini M, Jarvinen J, Bahrami K, Tampio J, Bartoccini F, Riihela P, et al.
ACS Med Chem Lett
. 2024 Dec;
15(12):2121-2128.
PMID: 39691535
This research investigates boronated tryptophans as potential boron delivery agents for boron neutron capture therapy (BNCT) of cancer. We synthesized both enantiomers of 5- and 6-boronotryptophans ( and ) using...
2.
Tampio J, Montaser A, Jarvinen J, Lehtonen M, Jalkanen A, Reinisalo M, et al.
Eur J Pharm Sci
. 2024 Oct;
203:106937.
PMID: 39419128
l-type amino acid transporter 1 (LAT1) is a membrane transporter responsible for carrying large, neutral l-configured amino acids as well as appropriate (pro)drugs into a cell. It has shown a...
3.
Matovic J, Jarvinen J, Sokka I, Imlimthan S, Aitio O, Sarparanta M, et al.
Molecules
. 2024 Sep;
29(17).
PMID: 39275111
Boron Neutron Capture Therapy (BNCT) is a cancer treatment which combines tumor-selective boron delivery agents with thermal neutrons in order to selectively eradicate cancer cells. In this work, we focus...
4.
Jarvinen J, Pulkkinen H, Rautio J, Timonen J
Pharmaceutics
. 2023 Dec;
15(12).
PMID: 38140004
Interest in the design of boronated amino acids has emerged, partly due to the utilization of boronophenylalanine (BPA), one of the two agents employed in clinical Boron Neutron Capture Therapy...
5.
Huttunen J, Tampio J, Jarvinen J, Montaser A, Markowicz-Piasecka M, Huttunen K
Chem Biol Interact
. 2023 Dec;
388:110833.
PMID: 38101600
Many chemotherapeutic drugs suffer from multidrug resistance (MDR). Efflux transporters, namely ATP-binding cassettes (ABCs), that pump the drugs out of the cancer cells comprise one major reason behind MDR. Therefore,...
6.
Auchynnikava T, Aarela A, Liljenback H, Jarvinen J, Andriana P, Kovacs L, et al.
ACS Omega
. 2023 Dec;
8(48):45326-45336.
PMID: 38075748
Pretargeted concept in positron emission tomography (PET) together with bioorthogonal chemistry is an elegant solution to study processes with slow pharmacokinetics by utilizing radiotracers labeled with short-lived radionuclides. Namely, radiotracers...
7.
Jarvinen J, Montaser A, Adla S, Leppanen J, Lehtonen M, Vellonen K, et al.
Eur J Pharm Sci
. 2023 Nov;
192:106637.
PMID: 37967656
Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is currently used clinically for treating hormone receptor-positive and human epidermal growth factor receptor 2 negative breast cancer. Additionally, it has the potential...
8.
Bahrami K, Jarvinen J, Laitinen T, Reinisalo M, Honkakoski P, Poso A, et al.
Mol Pharm
. 2022 Nov;
20(1):206-218.
PMID: 36394563
L-type amino acid transporter 1 (LAT1) transfers essential amino acids across cell membranes. Owing to its predominant expression in the blood-brain barrier and tumor cells, LAT1 has been exploited for...
9.
Matovic J, Jarvinen J, Sokka I, Stockmann P, Kellert M, Imlimthan S, et al.
ACS Omega
. 2022 Sep;
7(34):30376-30388.
PMID: 36061667
Glucose- and sodium-dependent glucose transporters (GLUTs and SGLTs) play vital roles in human biology. Of the 14 GLUTs and 12 SGLTs, the GLUT1 transporter has gained the most widespread recognition...
10.
Srisongkram T, Bahrami K, Jarvinen J, Timonen J, Rautio J, Weerapreeyakul N
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955600
Sesamol is a compound reported to have anti-melanogenesis and anti-melanoma actions. Sesamol, however, has low intracellular drug concentration and fast excretion, which can limit its benefits in the clinic. To...